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Abstract
Background: The aim of our work was to evaluate the potential impact of the European policy of testing for HIV
all individuals presenting with an indicator disease, to prevent late diagnosis of HIV. We report on a retrospective
analysis among individuals diagnosed with HIV to assess whether a history of certain diseases prior to HIV diagnosis
was associated with the chance of presenting late for care, and to estimate the proportion of individuals presenting
late who could have been diagnosed earlier if tested when the indicator disease was diagnosed.
Methods: We studied a large cohort of individuals newly diagnosed with HIV infection in 13 counselling and testing
sites in the Lazio Region, Italy (01/01/2004-30/04/2009). Considered indicator diseases were: viral hepatitis infection
(HBV/HCV), sexually transmitted infections, seborrhoeic dermatitis and tuberculosis. Logistic regression analysis was
performed to estimate association of occurrence of at least one indicator disease with late HIV diagnosis.
Results: In our analysis, the prevalence of late HIV diagnosis was 51.3% (890/1735). Individuals reporting at least one
indicator disease before HIV diagnosis (29% of the study population) had a lower risk of late diagnosis (OR = 0.7;
95%CI: 0.5-0.8) compared to those who did not report a previous indicator disease. 52/890 (5.8%) late presenters
were probably already infected at the time the indicator disease was diagnosed, a median of 22.6 months before
HIV diagnosis.
Conclusions: Our data suggest that testing for HIV following diagnosis of an indicator disease significantly decreases
the probability of late HIV diagnosis. Moreover, for 5.5% of late HIV presenters, diagnosis could have been anticipated if
they had been tested when an HIV indicator disease was diagnosed.
However, this strategy for enhancing early HIV diagnosis needs to be complemented by client-centred interventions
that aim to increase awareness in people who do not perceive themselves as being at risk for HIV.
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Background
Combination antiretroviral therapy (cART) has dramat-
ically changed the natural history of HIV infection by
substantially reducing associated morbidity and mortal-
ity [1]. However, the effectiveness of this treatment at
both the individual and population level is limited by the
fact that a substantial proportion of persons living with
HIV are unaware of their serostatus, and present for
clinical care when already at an advanced stage of infec-
tion. In Europe, almost 30% of HIV-infected persons still
remain undiagnosed [2] and the overall incidence of late
presentation may be as high as 50% of all HIV cases
[3,4]. In the United States (US), it is estimated that
nearly 1.1 million people are HIV-infected but approxi-
mately 25% of them are not aware of their infection [5];
in 2007, 54% of persons with HIV who entered into care
had a CD4 cell count below the threshold mentioned in
different guidelines for cART initiation [6].
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Different strategies have been proposed to address this
problem. In 2006, the US Centres for Disease Control
and Prevention (CDC) recommended routine HIV test-
ing for all individuals aged 13 to 64 years who come into
contact with the health system [7]. However, available
evidence suggests that uptake of routine HIV screening
varies greatly in different health care settings [8]. Some
studies showed that although the level of patient accept-
ability is high (>90%), the test offering rate may be
rather low due to staff-generated barriers, including attitu-
dinal barriers (patients are not perceived to be at risk and
therefore testing is not offered) [9,10].
In Europe another approach has been proposed,
which is based on routine testing of individuals pre-
senting with an “HIV indicator disease”, independent
of any risk assessment. These diseases include certain
infections that share a common mode of transmis-
sion with HIV, diseases whose onset is favoured by
HIV-induced immunodeficiency, and any other med-
ical condition associated with an undiagnosed HIV
prevalence greater than 0.1%, the prevalence value for
which delivering routine HIV testing resulted to be
cost-effective [11,12].
The main objective of this study was to assess retro-
spectively the potential impact of this policy on preventing
late HIV diagnosis in a cohort of newly HIV-diagnosed in-
dividuals. In particular, we estimated the association of
HIV indicator disease occurrence with late HIV diagnosis,
identifying variables associated with HIV testing after
the diagnosis of an indicator disease and estimating the
proportion of late presenting individuals who could have
been diagnosed earlier if tested when the indicator disease
was diagnosed.
Methods
Since January 2004, a prospective multi-centre observa-
tional study on newly diagnosed adults with HIV infec-
tion (SENDIH Study) has been conducted in 13 regional
counselling and testing sites of the Lazio region. Charac-
teristics and methods of the study have been previously
described [13,14]. Briefly, for all enrolled individuals, the
following information was collected in a standardized
case report form (see Additional file 1): socio-demographic
characteristics, laboratory data, HIV exposure category,
previous HIV tests and clinical history.
In particular, based on the frequencies observed in the
pilot study, the questionnaire collected information about
the following HIV indicator diseases: hepatitis B virus
(HBV) and hepatitis C virus (HCV) infection, syphilis, gon-
orrhoea, genital herpes, genital warts, infectious vaginitis,
seborrhoeic dermatitis and tuberculosis.
Regarding tuberculosis, even if it is already a generally
accepted practice to screen TB patients for HIV, often,
this recommendation is not followed. In addition, a
number of studies demonstrated that TB represents a
missed opportunity for HIV infection diagnosis [15,16].
The ethics committee of the coordinating centre, the
“L. Spallanzani” National Institute for Infectious Dis-
eases has approved the study [13].
In the analysis, we included all individuals enrolled up
to April 30, 2009 with a CD4 count determination avail-
able within 3 months of HIV diagnosis.
HIV exposure category was classified according to the
following modes of acquisition: intravenous drug use
(IDU); men who have sex with men (MSM); heterosex-
uals. Individuals infected through blood products and
those without a defined HIV exposure risk factor were
classified as “other/unreported”.
In a subset of individuals who also completed a self-
administered behavioural and clinical questionnaire, we
measured the concordance between the information on
each single indicator disease reported in the question-
naire and the data collected at enrolment by Cohen's
kappa statistic (K coefficient).
For patients who reported a previous HBV or HCV
infection at enrolment, we also checked serological sta-
tus in clinical and laboratory records and measured
the agreement between reported information and sero-
logical data.
Statistical analysis
A descriptive analysis was performed to describe the oc-
currence of an indicator disease before HIV diagnosis.
Univariable and multivariable logistic regression ana-
lysis were performed to estimate the association of HIV
indicator diseases with late diagnosis, categorized as
“late presentation” or “presentation with advanced HIV
disease”. As a measure of association, we calculated
the odds ratio (OR), multivariable logistic regression
odds ratio (MLR-OR) and their 95% confidence inter-
vals (95% CI).
Exposure variables: having had at least one HIV indi-
cator disease before HIV diagnosis (model 1); HIV test-
ing after an HIV indicator disease (model 2) and type
of indicator disease (grouped as: Hepatitis; Sexually
Transmitted Infections (STI); Seborrhoeic dermatitis/
Tuberculosis) (model 3).
Outcome variables: “Late presentation” was defined
when the individual had a CD4 count <350 cells/mmc
or an AIDS-defining event within 3 months of HIV
diagnosis [17].
“Presentation with advanced HIV disease” was defined
when the individual had a CD4 count <200 cells/mmc
or an AIDS-defining event within 3 months of HIV
diagnosis [17].
The covariates introduced in the multivariable models
were: gender, age (as a continuous variable), area of birth
(Italy versus another country), HIV exposure category
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(heterosexual contacts as a reference category) and a
previous HIV- negative test.
In order to estimate the chance that a person with at
least one HIV indicator disease will be diagnosed late,
we calculated the positive predictive value (PPV) of the
indicator diseases for late presentation.
Moreover, for 120 persons reporting more than one
indicator disease, we performed the chi-square test to
study the association between different combinations of
multiple indicator diseases and late presentation.
We performed a multivariable regression analysis in
order to compare the characteristics of individuals who
were tested for HIV with those who were not, after the
diagnosis of an indicator disease, adjusted for age, gen-
der, CD4 cell count, area of birth, risk factors, previous
negative test and type of indicator disease. A patient was
classified as tested for HIV after an indicator disease if
the patient first tested HIV-positive or tested negative
within 6 months after the indicator disease. For individ-
uals with more than one indicator disease, we consid-
ered the most recent one.
Since tuberculosis is considered an AIDS-defining ill-
ness, all statistical analysis were also performed exclud-
ing all individuals who reported tuberculosis in their
clinical history.
According to data derived from the CASCADE collab-
oration on HIV seroconverters, we estimated the pre-
sumed time since HIV infection for each individual. For
the purpose of the analysis we assumed that HIV in-
fection occurred 1.19, 4.19 and 7.94 years before the
first HIV positive test, respectively, for people with a
CD4 cell count <500 cells/mmc, <350 cells/mmc and <200
cells/mmc at the time of HIV diagnosis [18]. Taking into
account the estimated time since HIV infection, we ana-
lyzed data on individuals who reported the diagnosis of
an indicator disease and were not tested for HIV to
evaluate the proportion of individuals with late diagnosis
who could have been diagnosed earlier if tested at the
time the indicator disease was diagnosed.
Data were entered into an Access database, verified by
double entry and analyzed using SPSS package (version
17.00 SPSS Inc., Chicago, Illinois).
Results
Occurrence of HIV indicator diseases
Out of the 1,864 individuals enrolled up to April 30,
2009, 1,735 had a CD4 cell count performed within
3 months of the first HIV- positive test and were included
in the analysis. Late presenters were 51.3% (890/1735) and
presenters with advanced HIV disease were 34.2% (594/
1735). Table 1 shows the socio-demographic, clinical and
epidemiological characteristics of the whole study popula-
tion and late presenters. Five hundred individuals were for-
eign born (36% in Africa, 30% in South America; 20% in
Eastern Europe) and had a median time of residence in
Italy of 4 years (IQR: 1–9 years).
Twenty-nine percent (504/1735) of the individuals
reported at least one HIV indicator disease before HIV
diagnosis and 120 reported more than one, for a total
of 641 indicator diseases. Median time from indicator
disease to HIV diagnosis was 15.4 months (IQR: 0.9-
63.1 months).
Distribution of reported indicator diseases was: 210
viral hepatitis cases (126 HBV; 84 HCV); 382 STI cases
(195 syphilis, 67 gonorrhoea, 33 genital herpes, 85 geni-
tal warts, 2 infectious vaginitis), 38 cases of seborrhoeic
dermatitis and 11 cases of tuberculosis.
Concerning the 120 persons reporting more than one
indicator diseases, 37 reported two or more STI, 49
reported STI and hepatitis, 20 reported both HBV and
HCV infection and 14 reported seborrhoeic dermatitis/
tuberculosis with a STI or one type of hepatitis.
In a subset of 683 individuals who completed a self-
administered questionnaire, for each single indicator dis-
ease considered we observed a good concordance (k values
of 0.7 to 0.9) between the questionnaire and the data col-
lected at enrolment.
Among the 126 individuals who reported HBV infec-
tion, serological data were available for 113 and 95% of
them (107/113) were HBsAg and/or HBcAb -positive.
Among the 84 individuals who reported HCV infection,
serological data were available for 79, and 90% of them
(71/79) were anti-HCV- positive or HCV-RNA- positive.
Figure 1 shows the distribution of indicator diseases
by late presentation (CD4 <350 cells/mmc or an AIDS-
defining event).
Association of indicator diseases with late presentation
of HIV
Univariable regression analysis showed that individuals
who reported at least one indicator disease before HIV
diagnosis had a lower risk of late presentation (OR = 0.6;
95%CI: 0.5-0.7). The risk of late presentation significantly
increased for older individuals (OR = 1.05 for each year of
age; 95%CI: 1.04-1.06) and female gender (OR = 1.3; 95%
CI: 1.1-1.7), while it decreased for MSM (OR = 0.4; 95%CI:
0.3-0.5), IDUs (OR = 0.7; 95%CI: 0.4-0.9) and individ-
uals with a previous HIV negative test (OR = 0.2; 95%CI:
0.2-0.3). The above estimated associations were unchanged
after all individuals who reported tuberculosis were ex-
cluded from the analysis.
With regard to the type of indicator disease, compared
to individuals who did not report an indicator disease be-
fore HIV diagnosis, the risk of late presentation was lower
for those reporting a STI (OR = 0.4; 95%CI: 0.3-0.5) while
it increased for those reporting seborrhoeic dermatitis/
tuberculosis (OR = 4.8; 95%CI: 2.0-11.4). Excluding all
individuals with previous tuberculosis, the risk of late
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presentation for individuals reporting a STI was not modi-
fied, while it increased for those reporting seborrhoeic
dermatitis (OR = 6.1; 95%CI: 2.1-17.5).
Multivariable logistic regression models, shown in
Table 2, confirmed that the occurrence of at least one
indicator disease was associated with a reduced risk of
late presentation (MLOR= 0.7; 95%CI: 0.5-0.8) (model 1).
Moreover, the probability of late presentation was signifi-
cantly lower for individuals tested for HIV after an indica-
tor disease (MLOR= 0.5; 95%CI: 0.4-0.7) compared with
Table 1 Characteristics of study population and late presenters (CD4 <350 cells/mmc)
Variable Study population HIV Late presenters
N = 1735 (CD4 <350 cells/mmc)
N (%) N = 890
N (%)
Median age (min-max) 36 yy (18–86) 39 yy (18–86)
Gender
Male 1360 78.4% 676 76.0%
Area of birth
Not Italy 500 28.8% 273 30.7%
HIV exposure category
Heterosexual 695 40.1% 428 48.0%
MSM 835 48.2% 337 37.9%
IDU 136 7.8% 70 7.9%
Other/unreported 69 3.9% 55 6.2%
Previous HIV- negative test 780 45% 240 27.0%
Previous HIV- negative test within 6 months 111 6.4% - -
CD4 cells/mmc
≥350 845 48.7% - -
200-349 296 17.1% - -
≤199 and AIDS 594 34.2% - -
AIDS 330 17.5% 324 36.4%
HIV indicator disease 504 29% 212 23.8%











No Late presenters Late presenters 
Figure 1 Distribution of indicator diseases by late presentation (CD4 < 350 cells/mmc or an AIDS-defining event).
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individuals who did not report a previous indicator disease
(model 2).
If we consider the type of indicator disease, the multi-
variable analysis (model 3) showed that the risk of late
presentation was significantly lower for individuals who
reported diagnosis of a STI (MLOR = 0.5; 95%CI: 0.4-
0.6) compared to individuals who did not report a previ-
ous indicator disease, while individuals with seborrhoeic
dermatitis or tuberculosis had a higher risk of late presen-
tation (MLOR= 4.2; 95%CI: 1.7-10.6). Excluding all indi-
viduals with tuberculosis from the analysis, the measures
of association (MLOR) were unchanged in all 3 models, ex-
cept for seborrhoeic dermatitis in model 3 (MLOR= 5.8;
95%CI: 2.0-17.0).
The multivariable regression analysis for presentation
with advanced HIV disease confirmed the results of
three multivariable regression models for late presenters
(data not shown).
The overall PPV of these indicator diseases for late
presentation was 0.4, varying from 0.9 for seborrhoeic
dermatitis to 0.5 for hepatitis and 0.4 for STI. In particular,
both for hepatitis and STI, women had higher chance to be
HIV late presenter (PPV = 0.7, PPV = 0.5 respectively) than
heterosexual men (PPV = 0.6, PPV = 0.4 respectively) and
MSM (PPV= 0.4, PPV = 0.3 respectively).
Concerning the 120 persons reporting more than one
indicator diseases, the proportion of late presenters who
reported two or more STI (27.0%) was significantly lower




Model 1a Model 2b Model 3c
Age (per year old) 1.05 (1.04-1.07) 1.05 (1.04-1.07) 1.05 (1.04-1.06)
Gender
Male 676/1360 (49.7%) 1 1 1
Female 214/375 (57%) 0.9 (0.7-1.2) 0.9 (0.6-1.2) 0.9 (0.7-1.2)
Area of birth
Italy 617/1235 (50%) 1 1 1
Not Italy 273/500 (54.6%) 1.5 (1.2-1.9) 1.5 (1.2-1.9) 1.5 (1.2-1.9)
HIV exposure category
Heterosexual 428/695 (61.6%) 1 1 1
MSM 337/835 (40.3) 0.5 (0.4-0.7) 0.5 (0.4-0.7) 0.6 (0.4-0.7)
IDU 70/136 (51.5%) 0.8 (0.5-1.2) 0.8 (0.5-1.2) 0.8 (0.5-1.1)
Other/unreported 55/69 (79.7%) 1.2 (0.7-2.1) 1.1 (0.6-2.1) 1.2 (0.7-2.1)
Indicator Disease (ID)
No 678/1231 (55.1%) 1 - -
Yes 212/504 (42.1%) 0.7 (0.5-0.8) - -
ID§ and HIV test
No ID 678/1231(55%) - 1 -
ID tested for HIV 129/358 (36%) - 0.5 (0.4-0.7) -
ID not tested for HIV 71/123 (57.7%) - 1.2 (0.8-1.8) -
Missing data 12/23 (52.2%) - 0.8 (0.3-1.9) -
Type of ID§
No ID 678/1231(55%) - - 1
STI* 95/302 (31.5%) - - 0.5 (0.4-0.6)
Hepatitis 82/161 (50.3%) - - 0.8 (0.6-1.2)
Seb. dermatitis or TB** 35/41 (85%) - - 4.3 (1.7-10.6)
statistically significant MLOR are shown in bold.
§ ID Indicator Diseases.
* STI: sexually transmitted infections.
** TB: Tuberculosis.
a: association of HIV indicator disease and late presentation adjusted for age, gender, area of birth, HIV exposure category and indicator disease.
b: association of HIV indicator disease and late presentation adjusted for age, gender, area of birth, HIV exposure category and HIV testing after an HIV
indicator disease.
c: association of HIV indicator disease and late presentation adjusted for age, gender, area of birth, HIV exposure category and type of indicator disease.
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than the proportion of those who reported STI and hepa-
titis (38.8%) or both HBV and HCV infection (65.0%), or
seborrhoeic dermatitis/tuberculosis with a STI or one type
of hepatitis (64.3%) (p = 0.013).
Missed opportunities for timely HIV diagnosis following
an indicator disease
Among the 504 individuals who reported at least one indi-
cator disease, with respect to this diagnosis, 202 (40.1%)
first tested HIV-positive within 6 months, 156 (30.9%)
tested HIV- negative at least once in the following period
and 123 (24.4%) were not tested for HIV following the in-
dicator disease. For 23 (4.6%) individuals, information on
previous HIV- negative tests was not available.
The multivariable regression analysis (Table 3) showed
that individuals without a defined HIV exposure risk fac-
tor (classified as “other/unreported” mode of acquisition)
were significantly less likely to be tested after an indica-
tor disease than heterosexuals (MLOR = 0.15; CI 95%:
0.03- 0.84). On the contrary, those who had performed a
previous HIV negative test were significantly more likely
to be tested (MLOR = 3.9; CI 95%: 2.4 – 6.6). The re-
gression analysis results were not affected by the exclu-
sion of patients with tuberculosis.
Based on our assumption of the presumed time since
HIV infection, 59 individuals (3.4% of the study popu-
lation) who were diagnosed with an indicator disease
and were not tested for HIV thereafter could already
have been HIV- infected at the time of the indicator
disease and their diagnosis could have been anticipated
a median of 18.6 months.
Among the 890 late presenters (CD4 < 350 cells/mmc),
52 individuals (5.8%) could already have been infected with
HIV at the time of the indicator disease, which was diag-
nosed a median of 22.6 months before HIV. The majority
of these 52 individuals were male (84.6%) with a median
age of 39 years (range 22–71 years) and Italian (88.5%)
With regard to HIV exposure category, individuals infected
through homosexual contacts accounted for 57.7%, hetero-
sexual contacts accounted for 28.8%, and those through
injecting drug use for 9.6% of the total. More than one half
(31/52) reported a STI as an indicator disease and 44.2%
were never tested before HIV diagnosis. An additional 27
(3%) late presenters reported an indicator disease before
HIV diagnosis that, according to our assumption, occurred
before the estimated time of HIV infection.
Among the 594 presenters with advanced HIV disease
(CD4 < 200 cells/mmc), 33 (5.5%) could already have
Table 3 Multivariable regression model to compare characteristics of individuals tested for HIV after an HIV indicator
disease vs. individuals not tested after an HIV indicator disease
Variable Tested for HIV after indicator disease/Total N = 481 (%) * MLOR (95%CI)
Median age (min-max) 36 (20–86) 0.99 (0.97-1.01)
Median CD4 (min-max) 416 (2–1458) 1.001 (1–1.002)
Gender
Female 35/51 (68.6%) 1
Male 323/430 (75.1%) 0.7 (0.3-1.6)
Area of birth
Italy 278/379 (73.4%) 1
Not Italy 80/102 (78.4%) 1.7 (0.9-3.1)
HIV exposure category
Heterosexual 80/113 (70.8%) 1
MSM 239/311 (76.8%) 0.7 (0.3-1.3)
IDU 35/47(74.5%) 0.5 (0.2-1.2)
Other/unreported 4/10 (40%) 0.2 (0.03-0.8)
Previous negative test
No 93/163 (57.1%) 1
Yes 248/297 (83.5%) 4.1 (2.5-6.8)
Type of indicator diseases
STI 220/298(73.8%) 1
Hepatitis 113/143 (79.0%) 1.7 (0.9-3.1)
Seborrhoeic dermatitis or TB** 25/40 (62.5%) 1.3 (0.6-3.2)
statistically significant MLOR are shown in bold.
* The 23/504 subjects with an HIV indicator disease were excluded from analysis because not all data were available.
** TB: Tuberculosis.
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been infected at the time of the indicator disease which
was diagnosed a median of 41.6 months before HIV.
Discussion
Routine HIV testing in individuals presenting with
diseases/conditions which may indicate the presence
of HIV infection, the so-called indicator diseases, has
been recommended to reduce undiagnosed HIV infection
[11,12]. In particular, according to the guidance outlined by
the HIV in Europe initiative, routine testing of any person
presenting with a condition associated with an undiag-
nosed HIV prevalence of >0.1% is cost-effective and pro-
motes earlier diagnosis of HIV infection [12].
In our multi-centre study, we found that almost thirty
percent of newly diagnosed adults with HIV infection
reported at least one indicator disease before HIV diag-
nosis, and that being tested for HIV within six months
of being diagnosed with an indicator disease reduced the
risk of late HIV presentation by 50%.
More than half of our study population had a late HIV
diagnosis, i.e. at a stage of their disease when, according
to current guidelines, they should have already started
cART, and 39% of the individuals were first diagnosed
with HIV at an advanced stage. These figures are con-
sistent with previous reports from industrialized coun-
tries. In Europe among 10,222 newly diagnosed HIV
infection cases with CD4 cell counts reported in 2009,
51% had a first CD4 cell count below 350/mmc [4] and
a series of surveys show that 29–39% of individuals with
a new HIV diagnosis have less than 200 CD4 cells/mmc
at first presentation [19]. Similarly, more than half of the
individuals enrolled in cohort studies in North America
from 1997–2007 had fewer than 350 CD4 cells/mmc
when they first presented for HIV care [6].
Factors associated with late diagnosis and presenta-
tion with advanced HIV disease in our study included
older age, being foreign born and having acquired HIV
infection through heterosexual contact. These results
agree with those from previous studies [20-22] and
suggest that individuals perceiving themselves as be-
ing at risk of infection, such as MSM and/or IDUs, are
more likely to be diagnosed earlier than individuals
who are not tested until the clinician evaluates the situ-
ation and recommends testing, such as foreigners and
older people.
On the other hand, we found that a previous diagnosis
of an HIV indicator disease followed by an HIV test
within six months significantly reduced the risk of late
presentation.
Almost thirty percent of our study population reported
at least one indicator disease before HIV diagnosis and
more than ten percent were diagnosed with HIV within
six months of being diagnosed with an indicator disease.
Taken together, these data support the hypothesis that
testing for HIV following a diagnosis of an indicator dis-
ease may significantly prevent late diagnosis.
To our knowledge, few reports have analyzed the asso-
ciation between diagnosis of an indicator disease and
probability of receiving an earlier HIV diagnosis [23-28].
Klein et al. have reviewed medical encounters before
HIV diagnosis in the US concluding that increased rec-
ognition of clinical indicators for HIV testing prompted
earlier HIV diagnosis in 22% of individuals [23]. Re-
cently, Ellis S. et al. found that in the United Kingdom,
among 1,112 newly diagnosed HIV-infected patients, a
quarter of them were identified as having missed an op-
portunity for earlier diagnosis [24]. Similar to our results,
Lo YC et al. found that in Taiwan, missed opportunities
for HIV testing were more common in individuals with
late diagnosis than in those with earlier diagnosis (23% vs.
15.8%), and individuals with late HIV diagnosis were more
likely than their counterparts to have received a diag-
nosis of seborrhoeic dermatitis (7.4% vs. 0.8%, p = 0.02)
for which HIV testing was not offered by the health care
provider [25].
In contrast with these results, in the study conducted
between 2001 and 2005 in a South Carolina health care
facility, Duffus et al. found that approximately 80% of
the health care visits before HIV diagnosis for both late
and early testers were for conditions not likely to prompt
HIV testing in a non-routine testing environment [26].
The authors concluded that a clinical risk-based testing
strategy, even if implemented successfully in their facility,
would still have missed an earlier diagnosis the majority of
the time.
In our study, the association with late diagnosis differed
according to the type of indicator disease considered. Indi-
viduals reporting a STI had the lowest risk of late diagno-
sis, while those reporting tuberculosis and seborrhoeic
dermatitis had an increased chance of being diagnosed at
an advanced stage of immunosuppression. This finding is
not surprising since the risk of persons with HIV develop-
ing tuberculosis significantly increases, parallel to their
increasing level of immunodeficiency [29]. Nevertheless,
it should be emphasized that patients with tuberculosis
should be routinely tested for HIV, since failure to diag-
nose and treat HIV in these patients could be detrimental
to survival [30]. It has also been shown that seborrhoeic
dermatitis generally occurs in individuals with CD4 cell
counts between 201–500 cells/mmc [31].
In our study population, although diagnosis of an indi-
cator disease reduced the overall risk of late diagnosis,
almost one fourth of the individuals were not tested for
HIV within six months of being diagnosed with the indi-
cator disease.
The probability of being tested for HIV following an
indicator disease didn’t differ for age, gender, CD4 cell
count or place of birth. Individuals who reported to have
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been previously tested for HIV had a higher probability of
being tested after an indicator disease; on the contrary,
those with an unreported mode of HIV acquisition had a
lower probability of being tested after an indicator disease.
It is difficult to interpret this result since individuals
with unreported modes of HIV acquisition may actually
include people with different risk behaviours [32]. How-
ever, one may speculate that individuals classified in this
group may be less likely to disclose risk behaviours to
the health care provider, thus not perceived as being at
risk and consequently less likely to be offered HIV test-
ing. Testing practices are highly dependent on the local
culture of the clinics, the individual practices of health
care workers and on perception of risk at an individual
level, often resulting in a missed opportunity to prevent
late diagnosis. Among US adults with positive serologic
test results for HBV and/or HCV, Krain et al. found that
only 40% had been tested for HIV and that older individ-
uals were less likely to be tested [33]. It has been shown
in a number of studies that people presenting with se-
vere HIV-related diseases frequently had a history of re-
peated previous contacts with medical services, both in
primary and secondary care, but were not tested for HIV
[7,23,28]. This may reflect, at least in some instances, at-
titudinal barriers of health care provider to offer test ra-
ther than low patient acceptability [9;10]. In an indicator
condition guided HIV testing strategy, all patients pre-
senting to any health care setting with specific indicator
conditions would be offered HIV testing independent of
risk assessment, as part of routine care.
Regarding the potential further impact of this strategy,
our data suggest that HIV diagnosis could have been an-
ticipated by a median of 22.6 months in almost 6% of
late presenters if they had been tested at the time the indi-
cator disease was diagnosed. We may have underestimated
this proportion. In fact, an additional 3% of late presenters
reported an indicator disease which occurred before our
estimated time of HIV infection, based on CD4 cell counts
at HIV diagnosis. Since there is variability in progression
of HIV infection, not taken into account in our analysis, it
is possible that some of these individuals could already
have been infected at the time the indicator disease was
diagnosed.
The indicators diseases considered in our study, are
conditions that a population-based case control study
conducted in Denmark [34] and the HIDES study (HIV
Indicator Diseases Across Europe Study) [9], showed to
be associated with HIV prevalence greater than 0.1%.
The above studies, that were published when our analysis
was already completed, have shown that an HIV preva-
lence above this threshold may be observed in a series of
clinical conditions that were not included in our analysis,
probably resulting in a underestimation of the overall im-
pact of this policy in preventing late HIV diagnosis.
Other potential limitations of our study need to be
considered. First, HIV-testing history and clinical history
were collected by patient interviews and this may imply
a recall bias. However, we found a good concordance
between the information on indicator diseases collected
at enrolment and those reported in a self-administered
questionnaire. Additionally, serological data provided evi-
dence of past HBV or HCV infection, respectively in 95%
and 90% of individuals who reported these infections at
enrolment. Second, for individuals who were not tested
for HIV following an indicator disease, we do not know if
HIV testing was recommended by the health care pro-
vider but was refused by the patient. Third, our study
population accounts for approximately 60% of the newly
diagnosed HIV infections reported every year to the Re-
gional HIV Surveillance System in Lazio region [13] and
therefore may not be fully representative.
Conclusions
A recent survey conducted in European countries has
shown that an HIV prevalence greater than 0.1% can be
recorded among patients presenting with some indicator
medical conditions, including those considered in the
present study [9]. Based on these results, the HIV in
Europe initiative strongly recommended routine HIV
testing of individuals presenting with these conditions,
independent of any risk assessment which may be a cost-
effective intervention to identify persons living with un-
diagnosed HIV infection [12].
Our data suggest that testing for HIV following diag-
nosis of an indicator condition significantly decreases
the probability of late HIV diagnosis, and thus reinforces
the indication to implement this strategy as an import-
ant component of a control policy for the HIV epidemic.
However, this policy needs to be complemented by
client-centred interventions that aim to increase aware-
ness in people who do not perceive themselves as being
at risk for HIV.
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